Pacira BioSciences (PCRX) Equity Ratio (2010 - 2026)

Pacira BioSciences' Equity Ratio history runs 17 years deep, the most recent figure standing at 0.54 for Q1 2026.

• In Q1 2026, Equity Ratio rose 7.51% year-over-year to 0.54; the TTM figure through Mar 2026 stood at 0.54 (up 7.51% YoY), while the FY2025 annual figure was 0.55, up 9.37% from the prior year.
• Equity Ratio was 0.54 for Q1 2026 at Pacira BioSciences, down from 0.55 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.56 in Q1 2024 to a low of 0.38 in Q1 2022.
• Historically, Equity Ratio has averaged 0.5 across 5 years, with a median of 0.5 in 2023.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio decreased 25.78% in 2022, then surged 34.39% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.46 in 2022, then rose by 19.89% to 0.55 in 2023, then fell by 9.35% to 0.5 in 2024, then gained by 9.37% to 0.55 in 2025, then dropped by 1.26% to 0.54 in 2026.
• The last three Equity Ratio figures came in at 0.54 (Q1 2026), 0.55 (Q4 2025), and 0.56 (Q3 2025), per Business Quant data.